NCT06782529 Knee Injections for Obese Patients With Knee Arthritis
| NCT ID | NCT06782529 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Mayo Clinic |
| Condition | Osteoarthritis of Knee |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-01-24 |
| Primary Completion | 2027-01-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 40 participants in total. It began in 2025-01-24 with a primary completion date of 2027-01-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess obese patients with knee arthritis and determine the non-inferiority of a low dose steroid treatment vs. standard dose steroid treatment for two knee outcome measures: pain and function.
Eligibility Criteria
Inclusion Criteria: • Patients with BMI ≥30 kg/m2 and radiograph-proven knee osteoarthritis who are interested in receiving a steroid injection for knee arthritis. Exclusion Criteria: * BMI \< 30 kg/m2 * Uncontrolled diabetics with a hemoglobin A1c \> 8% * No other treatment within the time frame of the study. * Patients that are undergoing physical therapy at the time of the study.
Contact & Investigator
Jeffrey P Nadwodny, DO
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06782529 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, up to 85 Years, studying Osteoarthritis of Knee. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06782529 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06782529 currently recruiting?
Yes, NCT06782529 is actively recruiting participants. Contact the research team at nadwodny.jeffrey@mayo.edu for enrollment information.
Where is the NCT06782529 trial being conducted?
This trial is being conducted at Jacksonville, United States.
Who is sponsoring the NCT06782529 clinical trial?
NCT06782529 is sponsored by Mayo Clinic. The principal investigator is Jeffrey P Nadwodny, DO at Mayo Clinic. The trial plans to enroll 40 participants.